These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 17331645)

  • 1. Opposite effects of the A2A receptor agonist CGS21680 in the striatum of Huntington's disease versus wild-type mice.
    Martire A; Calamandrei G; Felici F; Scattoni ML; Lastoria G; Domenici MR; Tebano MT; Popoli P
    Neurosci Lett; 2007 Apr; 417(1):78-83. PubMed ID: 17331645
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of CGS 21680, a selective adenosine A(2A) receptor agonist, on NMDA receptor function and expression in the brain of Huntington's disease mice.
    Ferrante A; Martire A; Armida M; Chiodi V; Pézzola A; Potenza RL; Domenici MR; Popoli P
    Brain Res; 2010 Apr; 1323():184-91. PubMed ID: 20138162
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Behavioral and electrophysiological effects of the adenosine A2A receptor antagonist SCH 58261 in R6/2 Huntington's disease mice.
    Domenici MR; Scattoni ML; Martire A; Lastoria G; Potenza RL; Borioni A; Venerosi A; Calamandrei G; Popoli P
    Neurobiol Dis; 2007 Nov; 28(2):197-205. PubMed ID: 17720507
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adenosine A2A receptor blockade differentially influences excitotoxic mechanisms at pre- and postsynaptic sites in the rat striatum.
    Tebano MT; Pintor A; Frank C; Domenici MR; Martire A; Pepponi R; Potenza RL; Grieco R; Popoli P
    J Neurosci Res; 2004 Jul; 77(1):100-7. PubMed ID: 15197743
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Remodeling of striatal NMDA receptors by chronic A(2A) receptor blockade in Huntington's disease mice.
    Martire A; Ferrante A; Potenza RL; Armida M; Ferretti R; Pézzola A; Domenici MR; Popoli P
    Neurobiol Dis; 2010 Jan; 37(1):99-105. PubMed ID: 19804830
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adenosine A2A receptor antagonism increases nNOS-immunoreactive neurons in the striatum of Huntington transgenic mice.
    Cipriani S; Bizzoco E; Gianfriddo M; Melani A; Vannucchi MG; Pedata F
    Exp Neurol; 2008 Sep; 213(1):163-70. PubMed ID: 18586241
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The A2A adenosine receptor rescues the urea cycle deficiency of Huntington's disease by enhancing the activity of the ubiquitin-proteasome system.
    Chiang MC; Chen HM; Lai HL; Chen HW; Chou SY; Chen CM; Tsai FJ; Chern Y
    Hum Mol Genet; 2009 Aug; 18(16):2929-42. PubMed ID: 19443488
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression, pharmacology and functional activity of adenosine A1 receptors in genetic models of Huntington's disease.
    Ferrante A; Martire A; Pepponi R; Varani K; Vincenzi F; Ferraro L; Beggiato S; Tebano MT; Popoli P
    Neurobiol Dis; 2014 Nov; 71():193-204. PubMed ID: 25132555
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CGS21680 attenuates symptoms of Huntington's disease in a transgenic mouse model.
    Chou SY; Lee YC; Chen HM; Chiang MC; Lai HL; Chang HH; Wu YC; Sun CN; Chien CL; Lin YS; Wang SC; Tung YY; Chang C; Chern Y
    J Neurochem; 2005 Apr; 93(2):310-20. PubMed ID: 15816854
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Functions, dysfunctions and possible therapeutic relevance of adenosine A2A receptors in Huntington's disease.
    Popoli P; Blum D; Martire A; Ledent C; Ceruti S; Abbracchio MP
    Prog Neurobiol; 2007 Apr; 81(5-6):331-48. PubMed ID: 17303312
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BDNF prevents NMDA-induced toxicity in models of Huntington's disease: the effects are genotype specific and adenosine A2A receptor is involved.
    Martire A; Pepponi R; Domenici MR; Ferrante A; Chiodi V; Popoli P
    J Neurochem; 2013 Apr; 125(2):225-35. PubMed ID: 23363456
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inactivation of adenosine A2A receptors reverses working memory deficits at early stages of Huntington's disease models.
    Li W; Silva HB; Real J; Wang YM; Rial D; Li P; Payen MP; Zhou Y; Muller CE; Tomé AR; Cunha RA; Chen JF
    Neurobiol Dis; 2015 Jul; 79():70-80. PubMed ID: 25892655
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adenosine A2A receptor blockade before striatal excitotoxic lesions prevents long term behavioural disturbances in the quinolinic rat model of Huntington's disease.
    Scattoni ML; Valanzano A; Pezzola A; March ZD; Fusco FR; Popoli P; Calamandrei G
    Behav Brain Res; 2007 Jan; 176(2):216-21. PubMed ID: 17123640
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Symptom-related changes of endocannabinoid and palmitoylethanolamide levels in brain areas of R6/2 mice, a transgenic model of Huntington's disease.
    Bisogno T; Martire A; Petrosino S; Popoli P; Di Marzo V
    Neurochem Int; 2008 Jan; 52(1-2):307-13. PubMed ID: 17664017
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Altered cortical glutamate receptor function in the R6/2 model of Huntington's disease.
    André VM; Cepeda C; Venegas A; Gomez Y; Levine MS
    J Neurophysiol; 2006 Apr; 95(4):2108-19. PubMed ID: 16381805
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adenosine and glutamate extracellular concentrations and mitogen-activated protein kinases in the striatum of Huntington transgenic mice. Selective antagonism of adenosine A2A receptors reduces transmitter outflow.
    Gianfriddo M; Melani A; Turchi D; Giovannini MG; Pedata F
    Neurobiol Dis; 2004 Oct; 17(1):77-88. PubMed ID: 15350968
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early increase in extrasynaptic NMDA receptor signaling and expression contributes to phenotype onset in Huntington's disease mice.
    Milnerwood AJ; Gladding CM; Pouladi MA; Kaufman AM; Hines RM; Boyd JD; Ko RW; Vasuta OC; Graham RK; Hayden MR; Murphy TH; Raymond LA
    Neuron; 2010 Jan; 65(2):178-90. PubMed ID: 20152125
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of adenosine A 2A receptors in the rat lumbar spinal cord and implications in the modulation of N-methyl-d-aspartate receptor currents.
    Guntz E; Dumont H; Pastijn E; d'Exaerde Ade K; Azdad K; Sosnowski M; Schiffmann SN; Gall D
    Anesth Analg; 2008 Jun; 106(6):1882-9. PubMed ID: 18499627
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adenosine A 2A receptor deficiency reduces striatal glutamate outflow and attenuates brain injury induced by transient focal cerebral ischemia in mice.
    Gui L; Duan W; Tian H; Li C; Zhu J; Chen JF; Zheng J
    Brain Res; 2009 Nov; 1297():185-93. PubMed ID: 19703429
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glutamate toxicity in the striatum of the R6/2 Huntington's disease transgenic mice is age-dependent and correlates with decreased levels of glutamate transporters.
    Estrada-Sánchez AM; Montiel T; Segovia J; Massieu L
    Neurobiol Dis; 2009 Apr; 34(1):78-86. PubMed ID: 19168136
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.